



Joint Symposium 7

EANM–EACVI Joint Symposium – Cardiovascular Committee

Tuesday, October 20, 15:00–16:30

Session Title

Stiff Heart, Think Amyloidosis

Chairpersons

Marc Dweck (Edinburgh, Scotland)

Olivier Lairez (Toulouse, France)

Programme

15:00–15:20 **Marc Dweck** (Edinburgh, Scotland): From the Clinical Points of View, What Else Do We Need?

15:20–15:45 **Simona Ben-Haim** (Jerusalem, Israel): Do We Need Signal Quantification?

15:45–16:10 **Raffaella Calabretta** (Vienna, Austria): Improved Phenotyping (New Tracers)

16:10–16:30 **Andreas Giannopoulos** (Zurich, Switzerland): Treatments and the Role of Imaging in Follow-Up

Educational Objectives

1. Identify unmet clinical needs in cardiac amyloidosis, beyond diagnosis, including early detection, risk stratification, prognostic assessment, and patient selection for emerging therapies, from a clinician's perspective.
2. Understand the added value and limitations of signal quantification in nuclear imaging, particularly bone scintigraphy and PET, and how quantitative approaches may improve diagnostic accuracy, disease staging, and longitudinal assessment.
3. Integrate advanced imaging techniques into patient phenotyping and follow-up, including novel tracers and multimodality imaging, to support therapeutic decision-making and monitor treatment response in cardiac amyloidosis.

Summary

Cardiac amyloidosis is an increasingly recognised cause of heart failure with a stiff or restrictive phenotype. This joint session between EANM and EACVI focuses on the evolving role of cardiovascular imaging beyond diagnosis. From a clinical perspective, the session will address unmet needs in early detection, phenotyping, prognostic assessment, and patient selection for disease-modifying therapies. The added value of signal quantification in nuclear imaging will be discussed, as well as the contribution of novel tracers to improved disease characterisation. Finally, the session will highlight the role of multimodality imaging in treatment monitoring and follow-up in cardiac amyloidosis.

Key Words

Cardiac Amyloidosis; Multimodality Imaging; Nuclear Cardiology; Signal Quantification; Disease Phenotyping; Treatment Monitoring